Correlation between 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in patients with Parkinson’s disease: a pilot study

• Autor(a) principal: Arena,Julieta E.
• Data de Publicação: 2021
• Outros Autores: Urrutia,Leandro, Falasco,Germán, Leon,Magdalena Ponce de, Vazquez,Silvia, Rossi,Malco, Merello,Marcelo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Radiologia Brasileira (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842021000400232
• topic: Parkinson disease/diagnostic imaging; Parkinsonian disorders/diagnostic imaging; Tomography, emission-computed, single-photon/methods; Positron-emission tomography/methods; Tropanes/pharmacokinetics; Dihydroxyphenylalanine/analogs & derivatives

Abstract Objective: To determine whether technetium-99m-labeled tropane derivative single-photon emission computed tomography (99mTc-TRODAT-1 SPECT) provides results comparable to those of the less widely available, less accessible tool fluorine-18-labeled fluorodopa positron-emission tomography (18F-FDOPA PET) in the setting of a movement disorders clinic. Materials and Methods: In this prospective pilot study, eight subjects with a clinical diagnosis of Parkinson’s disease were randomly selected from among patients under treatment at a movement disorders clinic and submitted to 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET. The results were read by two experienced observers, and a semiquantitative analysis was performed. Results: The visual and semiquantitative analyses were concordant for all studies, showing that radiotracer uptake in the contralateral striatum on the most affected side was lower when 99mTc-TRODAT-1 SPECT was employed. The semiquantitative analysis demonstrated a significant correlation between 18F-FDOPA PET and 99mTc-TRODAT-1 SPECT (r = 0.73; p < 0.01). Conclusion: It appears that 99mTc-TRODAT-1 SPECT is a valid option for the study of dopaminergic function in a clinical setting.